Introduction:
Yposkesi plans to open new bioproduction site with an investment of US$65. 3 million (€60 million) for manufacturing cell and gene therapies.
Features:
This project aims to double the current cGMP manufacturing space to 10,000 square meters (100,000 square feet) in response to the supply of viral vectors – essential components in the gene delivery systems used to produce gene and cell therapy (C>) products.
The facility's design comprises six Upstream Process (USP) and two Downstream Process (DSP) clean rooms. Of particular note is the remarkable increase in Yposkesi's bioreactor capacity, rising from 2,000 liters to an impressive 7,000 liters.
The facility also encompasses fill and finish capabilities, including semi-automated suites capable of handling a total of 12,000 vials per year.
The newly designed facility boasts state-of-the-art features that will enable the more efficient and cost-effective production of advanced therapies.
By increasing its production capacity twofold, the facility will be able to accommodate up to 75 batches annually.
The new site is anticipated to achieve full operational status by 2024. This facility will generate approximately 90 new job opportunities.
Specifications:
Name Yposkesi
Type New Construction
Budget US$65. 3 million (€60 million)
Year 2024
